Takeru Wakatsuki

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study

Shohei Udagawa, Chihiro Ishizuka, Hiroki Osumi, Toshiharu Hirose et autres

BACKGROUND: Fruquintinib has demonstrated survival benefits in patients with previously treated metastatic colorectal cancer (mCRC) in phase III trials. However, real-world data in Japanese patients remain limited. This study evaluated the effectiveness and safety of fruquintinib in routine clinical practice. METHODS: We …

jp (code pays fourni par la source)

Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer

Shohei Udagawa, Hiroki Osumi, Senzo Taguchi, Tatsuki Noguchi et autres

BACKGROUND: Total neoadjuvant therapy (TNT) is the standard treatment for locally advanced rectal cancer (LARC). Few studies have focused on the toxicity of TNT. Moreover, the differences in safety and tolerability between radiotherapy-first and chemotherapy-first strategies remain unclear. This study aimed to …

jp (code pays fourni par la source)

High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer

Koichiro Yoshino, Hiroki Osumi, Akira Ooki, Shohei Udagawa et autres

BACKGROUND: Oxaliplatin (OXA), a key cytotoxic agent used in the treatment of gastrointestinal cancers, is frequently discontinued due to hypersensitivity reactions (HSRs). We developed a protocol to mitigate HSRs and assessed its clinical efficacy. METHODS: We retrospectively analyzed HSRs in patients with …

jp (code pays fourni par la source)

A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with Neo RAS wild-type metastatic colorectal cancer (C-PROWESS trial).

Hiroki Osumi, Tadamichi Denda, Manabu Shiozawa, Atsuo Takashima et autres

3546 Background: Previous studies have demonstrated favorable efficacy of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in metastatic colorectal (mCRC) patients with Neo RAS wild type (WT), ie, conversion of RAS status from mutant to WT following treatment. This multicenter, single-arm, …

jp (code pays fourni par la source)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer

Koichiro Yoshino, Manabu Takamatsu, Akira Ooki, Keisho Chin et autres

BACKGROUND: Intratumoral HER2 heterogeneity has been associated with poor response to trastuzumab-based chemotherapy in HER2-positive gastric cancer. However, its clinical significance in patients treated with trastuzumab deruxtecan (T-DXd) remains unclear. METHODS: Patients with advanced HER2-positive gastric cancer who received T-DXd as second-line …

jp (code pays fourni par la source)

Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023

Keitaro Shimozaki, A. Ooki, Kaoru Yoshikawa, K. Yoshino et autres

Background: Although the emergence of multiple therapeutic agents has benefited patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), chronological improvements in treatment outcomes for real-world patients remain unclear. Objectives: The present study aimed to evaluate the treatment …

jp (code pays fourni par la source)

Usefulness of pharmacy outpatient clinic follow‑up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer

Masashi Nakamura, Takashi Yokokawa, Kazuyoshi Kawakami, Yuka Kimura et autres

Capecitabine plus oxaliplatin (CAPOX) is a frequently used treatment regimen for colorectal and gastric cancer as postoperative adjuvant chemotherapy. Nausea, vomiting and diarrhea are reported to be the main causes of decreased adherence to CAPOX therapy. The Cancer Institute Hospital, Japanese Foundation …

jp (code pays fourni par la source)

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka, Shuichi Hironaka et autres

BACKGROUND: While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. OBJECTIVE: The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric …

jp (code pays fourni par la source)

Figure S4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki et autres

In vivo therapeutic experiments using other tumor models (related to Figure 4)

Figure S5 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki et autres

FCM gating strategy (related to Figure 4)

Table 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki et autres

Summary of PFS and OS of the two groups divided by the cutoff values of ANGPTL3.

Figure 2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki et autres

High plasma ANGPTL3 levels are significantly associated with poor prognosis of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values before treatment, and significant differences in PFS …